Immunic Current Liabilities vs Total Assets Analysis
IMUX Stock | USD 1.27 0.06 4.96% |
Trend analysis of Immunic balance sheet accounts such as Other Current Liabilities of 19.9 M or Total Current Liabilities of 26 M provides information on Immunic's total assets, liabilities, and equity, which is the actual value of Immunic to its prevalent stockholders. By breaking down trends over time using Immunic balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Immunic |
About Immunic Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Immunic at a specified time, usually calculated after every quarter, six months, or one year. Immunic Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Immunic and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Immunic currently owns. An asset can also be divided into two categories, current and non-current.
Immunic Balance Sheet Chart
Immunic Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Immunic uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Immunic's Short Term Debt is fairly stable compared to the past year. Non Current Liabilities Other is likely to rise to about 1.2 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 955.9 K in 2024. Add Fundamental
Total Assets
Total assets refers to the total amount of Immunic assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Immunic books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Immunic balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Immunic are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Immunic's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunic current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.Selling General Administrative is likely to drop to about 14 M in 2024. Issuance Of Capital Stock is likely to drop to about 810.4 K in 2024
2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 66K | 1.0M | 3.1M | 3.2M | Interest Income | 66K | 1.0M | 3.1M | 3.2M |
Immunic fundamental ratios Correlations
Click cells to compare fundamentals
Immunic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunic fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 66.0M | 167.9M | 139.1M | 127.8M | 54.3M | 81.3M | |
Other Current Liab | 343K | 4.7M | 585K | 8.2M | 18.9M | 19.9M | |
Total Current Liabilities | 7.1M | 8.4M | 11.4M | 13.1M | 24.7M | 26.0M | |
Total Stockholder Equity | 58.4M | 158.8M | 127.1M | 113.7M | 28.9M | 27.5M | |
Property Plant And Equipment Net | 713K | 1.1M | 1.1M | 1.8M | 1.8M | 1.4M | |
Net Debt | (28.8M) | (126.8M) | (86.3M) | (105.2M) | (45.3M) | (47.6M) | |
Retained Earnings | (59.9M) | (103.9M) | (196.9M) | (317.3M) | (410.9M) | (390.3M) | |
Accounts Payable | 2.4M | 3.7M | 3.7M | 4.3M | 5.1M | 3.9M | |
Cash | 29.4M | 127.5M | 86.9M | 106.7M | 46.7M | 64.0M | |
Non Current Assets Total | 33.7M | 34.1M | 34.1M | 1.9M | 1.8M | 1.7M | |
Cash And Short Term Investments | 29.4M | 127.5M | 86.9M | 116.4M | 46.7M | 66.0M | |
Common Stock Shares Outstanding | 7.7M | 15.7M | 23.7M | 31.8M | 44.3M | 46.5M | |
Liabilities And Stockholders Equity | 66.0M | 167.9M | 139.1M | 127.8M | 54.3M | 81.3M | |
Non Current Liabilities Total | 520K | 679K | 584K | 992K | 639.0K | 607.0K | |
Other Current Assets | 2.9M | 1.2M | 18.1M | 9.5M | 5.2M | 4.1M | |
Other Stockholder Equity | 53.7M | 266.8M | 324.2M | 427.9M | 436.1M | 245.3M | |
Total Liab | 7.6M | 9.1M | 12.0M | 14.1M | 25.4M | 26.6M | |
Property Plant And Equipment Gross | 713K | 1.1M | 1.1M | 1.8M | 1.8M | 1.4M | |
Total Current Assets | 32.2M | 133.7M | 105.0M | 125.9M | 52.5M | 70.8M | |
Accumulated Other Comprehensive Income | (1.4M) | (4.1M) | (252K) | 3.0M | 3.8M | 3.9M | |
Non Currrent Assets Other | 108K | 37K | 42K | 43K | 38.7K | 36.8K | |
Net Tangible Assets | 25.4M | 125.8M | 94.1M | 113.7M | 130.7M | 80.6M | |
Retained Earnings Total Equity | (59.9M) | (103.9M) | (196.9M) | (317.3M) | (285.6M) | (299.8M) | |
Capital Surpluse | 119.6M | 266.8M | 324.2M | 427.9M | 492.1M | 326.3M | |
Non Current Liabilities Other | 520K | 679K | 584K | 992K | 1.1M | 1.2M | |
Property Plant Equipment | 80K | 203K | 1.1M | 294K | 264.6K | 251.4K | |
Other Assets | 37K | 42K | 943K | 43K | 49.5K | 47.0K | |
Net Receivables | 408K | 1.6M | 2.2M | 2.7M | 703K | 1.3M | |
Net Invested Capital | 58.4M | 158.8M | 127.1M | 113.7M | 28.9M | 27.5M | |
Net Working Capital | 25.2M | 125.3M | 93.6M | 112.8M | 27.8M | 26.4M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Immunic Stock analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Transaction History View history of all your transactions and understand their impact on performance | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.11) | Return On Assets (0.68) | Return On Equity (1.31) |
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.